Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01275 (
glucagon
)
26,492
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
L-Asparaginase, an effective agent in the treatment of acute lymphoblastic leukemia, may induce a diabetic state. The pathogenesis of the diabetogenic effect was studied in cultured pancreatic islets. Mean serum concentrations in three children with acute lymphoblastic leukemia were 2.4 U/mL (range 1.4-4.5) before and 31.5 U/mL (range 18.6-51.8) immediately after an intravenous injection of 1000 U/kg
L-asparaginase
. Glucose-induced insulin release from pancreatic islets of rat and man was measured after 3 and 7 days of culture in media with or without clinically relevant concentrations of Escherichia coli
L-asparaginase
(0.01-100 U/mL). After culture, the remaining insulin,
glucagon
, and DNA in the islets were determined. After 7 days of culture of adult rat or human islets, both the accumulation of insulin in the medium and the content of insulin and
glucagon
in the islets were significantly reduced in the presence of 100 U/mL
L-asparaginase
compared with controls. Addition of 10(-6) M hydrocortisone to the culture medium enhanced this effect. In newborn rat islets a significant reduction in insulin release and content was observed already in the presence of 0.1 U/mL
asparaginase
, whereas the
glucagon
content was unchanged. Removal of the drug resulted in partial recovery of the insulin secretion. To elucidate the mechanisms of of action of the drug, insulin biosynthesis was studied in islets cultured in asparagine-free medium with or without
asparaginase
. No difference in biosynthesis was seen between media with or without asparagine, whereas 0.1 U/mL
asparaginase
caused about a 50% reduction under both conditions.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Direct long-term effects of L-asparaginase on rat and human pancreatic islets. 267 5
Ten children with acute lymphocytic leukemia developed transient diabetes mellitus during treatment with
L-asparaginase
and prednisone. Serum glucose, plasma insulin, and plasma
glucagon
levels were measured when the patients were hyperglycemic. Six of the children were restudied several months later when there were no clinical or laboratory signs of glucose intolerance. Hyperglycemia induced by
L-asparaginase
and prednisone was associated with depression of plasma insulin and, despite the inhibiting action of
L-asparaginase
on protein synthesis, a corresponding elevation of plasma
glucagon
. Thus patients with diabetes mellitus induced by
L-asparaginase
and prednisone have relative hyperglucagonemia similar to other patients with diabetes mellitus.
...
PMID:Relative hyperglucagonemia in L-asparaginase-and prednisone-induced glucose intolerance in management of acute lymphocytic leukemia. 634 Sep 6
The effect of arginine infusion on blood glucose and plasma levels of insulin, C-peptide and
glucagon
has been studied in leukemic children before and after treatment with
L-asparaginase
(10,000 U/m2/day for 10 days). Therapy induced a significant reduction in basal and peak blood glucose, insulin and C-peptide levels, while
glucagon
was unmodified. The conserved C-peptide-insulin molar ratio suggests the interference of
L-asparaginase
with proinsulin synthesis. In conclusion our results prove a decreased insulin reserve with a preserved, although reduced, beta-cell function.
...
PMID:Pancreatic endocrine function in leukemic children treated with L-asparaginase. 676 89